Reclast (Zoledronic Acid) in Children Under 12: Developmental Impact

What Is Zoledronic Acid and Why Is It Used in Young Children?

Zoledronic acid is a third-generation nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase. In adults, the brand Reclast is FDA-approved for postmenopausal osteoporosis, Paget disease of bone, and glucocorticoid-induced osteoporosis. The brand Zometa (a lower-volume formulation) carries approval for hypercalcemia of malignancy and bone metastases. Neither formulation carries approval for children under 12. [1]

Pediatric use is driven by conditions that cause severe, early-onset bone fragility. Osteogenesis imperfecta (OI) affects roughly 1 in 15,000 to 20,000 births and is the most common indication. Fibrous dysplasia, glucocorticoid-induced osteoporosis from chronic disease treatment, and hypercalcemia secondary to malignancy round out the main off-label uses in this age group. [2]

Why Zoledronic Acid Over Pamidronate in Under-12s?

Pamidronate given as monthly IV cycles has been the dominant pediatric bisphosphonate for two decades. Zoledronic acid offers a shorter infusion time (15 to 45 minutes vs. 3 days per cycle) and less frequent dosing (every 6 to 12 months vs. Monthly), which reduces hospitalization burden for families. A 2013 randomized trial by Barros et al. (N=39 children with OI) found zoledronic acid produced equivalent lumbar spine bone mineral density (BMD) gains to pamidronate at 12 months, with no significant difference in fracture rates. [3]

FDA Regulatory Status

The FDA has not approved zoledronic acid for any pediatric indication under age 12. Prescribers using it in this population are acting under the off-label use authority granted by the FDA's regulations on physician prescribing. Informed consent conversations must specifically address this regulatory gap. [1]

How Zoledronic Acid Affects Bone Development in Children

Bone development in children is a dynamic process involving endochondral ossification at growth plates, continuous bone modeling, and peak bone mass accrual that extends into the mid-twenties. Introducing a potent, long-lived antiresorptive agent into this process carries both benefits and risks that differ substantially from adult physiology.

Effects on Growth Plates

Growth plate (physis) cartilage undergoes rapid cellular turnover. Bisphosphonates accumulate at sites of active mineralization, including the growth plate, where they slow chondrocyte apoptosis and delay primary spongiosa resorption. The resulting dense metaphyseal bands visible on plain radiographs are sometimes called "zebra lines" or bisphosphonate bands. They are histologically benign but serve as a radiographic record of each treatment cycle. [4]

Animal data have shown that high-dose bisphosphonate exposure can impair longitudinal bone growth. In a rat model, zoledronic acid at supratherapeutic doses reduced femoral length by approximately 8% compared with controls. Doses closer to the human therapeutic range produced smaller or no measurable effects on femoral length. [5]

Human data are more reassuring. A 5-year follow-up of 94 children with OI treated with pamidronate (the closest human analog with long-term data) showed no significant reduction in height Z-score compared with untreated OI patients. Because pamidronate and zoledronic acid share the same mechanism and skeletal distribution, these data are often cited when counseling families about zoledronic acid. Direct long-term height data for pediatric zoledronic acid are more limited. [6]

Cortical Versus Trabecular Bone

Zoledronic acid preferentially increases trabecular BMD, which is consistent with its mechanism of suppressing osteoclast-driven turnover in high-surface-area cancellous bone. In children with OI, lumbar spine (predominantly trabecular) Z-scores improve faster than femoral neck (more cortical) Z-scores. A 2019 analysis of 62 children with OI type I to IV treated with zoledronic acid 0.05 mg/kg every 6 months showed a mean lumbar spine Z-score improvement of +1.3 SD at 24 months (P<0.001 vs. Baseline). Femoral neck Z-score improved +0.7 SD over the same period. [7]

Long-Term Skeletal Half-Life

The skeletal half-life of zoledronic acid exceeds 10 years in adults. Pediatric data on skeletal retention are sparse, but because children have faster bone turnover, some models suggest faster release compared with adults. The clinical implication is that the drug continues to suppress resorption for years after the last infusion. This is clinically useful for fracture prevention but means that unintended effects on remodeling could persist well beyond the treatment period. [8]

Growth and Pubertal Development: What the Evidence Shows

Linear Growth

Concern about bisphosphonate-impaired linear growth is one of the most common questions clinicians face when counseling parents of children with OI or fibrous dysplasia. Current pediatric data, though not definitive, do not show that therapeutic doses of zoledronic acid meaningfully suppress linear growth.

A retrospective cohort by Letocha et al. Examined 18 children with severe OI (types III and IV) treated with intravenous pamidronate over a median of 3.7 years. Standing height Z-score did not change significantly compared with natural history data for OI. Similar findings have been reported in smaller zoledronic acid cohorts. [6]

Monitoring height velocity every 6 months is considered standard practice at centers with pediatric bone disease programs. Any child whose height velocity drops below the 5th percentile for age and sex warrants evaluation for causes beyond the bisphosphonate, including underlying disease progression.

Pubertal Timing

No published human data specifically link zoledronic acid to altered pubertal timing in children under 12. Animal studies using much higher doses have shown effects on gonadal axis function in rodents, but these doses are not clinically relevant. Tanner staging should still be documented at every clinic visit as part of routine developmental surveillance. [9]

Dental Development

Osteonecrosis of the jaw (ONJ) is a rare but serious complication of bisphosphonate therapy. In adults receiving high-dose Zometa for oncologic indications, ONJ incidence runs approximately 1 to 10% depending on duration and dose. In children receiving low-dose bisphosphonates for metabolic bone disease, published case reports number in the dozens globally; incidence is considered far lower. A 2022 systematic review identified 34 pediatric bisphosphonate-associated ONJ cases in the literature (most with pamidronate); only a minority involved zoledronic acid. Dental examination before starting therapy and annual dental review are recommended. [10]

Tooth eruption timing and root development should be monitored by a pediatric dentist familiar with bisphosphonate therapy. Parents should be told to report jaw pain, swelling, or non-healing oral ulcers promptly.

Renal Development and Safety in Under-12s

Zoledronic acid is cleared exclusively by the kidneys. In adults, the prescribing information requires withholding the drug if creatinine clearance drops below 35 mL/min. Children under 12 are still developing renal mass and concentrating capacity, and age-appropriate eGFR reference ranges differ substantially from adult norms. [1]

Pre-Infusion Renal Assessment

Serum creatinine and cystatin C-based eGFR (more accurate than creatinine alone in children) should be measured within 1 week before each infusion. Urinalysis with microscopy is also recommended to detect subclinical tubular injury. Acute tubular necrosis has been described after rapid zoledronic acid infusion in adults; pediatric cases are rare but documented. [11]

Infusion time matters. The prescribing information specifies a minimum 15-minute infusion for Zometa (4 mg/5 mL). Pediatric centers typically infuse the weight-based dose over 30 to 45 minutes to reduce peak plasma concentration and minimize renal exposure.

Hydration Protocol

Adequate hydration before and during infusion reduces renal tubular concentration of the drug. Most protocols recommend 10 mL/kg of normal saline over 1 hour before infusion in children who are not fluid-overloaded. Post-infusion oral hydration is encouraged for 24 hours.

Calcium and Vitamin D Homeostasis in Pediatric Patients

Hypocalcemia is the most common acute metabolic complication of bisphosphonate therapy in children. Zoledronic acid suppresses osteoclast activity rapidly, reducing calcium flux from bone. In children with vitamin D insufficiency, parathyroid hormone compensation may be inadequate, producing symptomatic hypocalcemia within 24 to 48 hours of infusion. [12]

Pre-Treatment Supplementation Protocol

Standard practice at pediatric metabolic bone centers includes:

• Confirming 25-hydroxyvitamin D above 20 ng/mL (50 nmol/L) before infusion, with a target of 30 to 50 ng/mL preferred.
• Starting elemental calcium supplementation (25 to 50 mg/kg/day in divided doses, not exceeding 1,000 mg/day) at least 48 hours before infusion.
• Continuing calcium and vitamin D for at least 2 weeks after infusion.

Serum calcium, phosphorus, and PTH should be checked 24 to 48 hours post-infusion in any child with a history of hypocalcemia, hypoparathyroidism, or severe vitamin D deficiency. [12]

Hypocalcemia Symptoms in Young Children

Children under 5 may present with hypocalcemia as irritability, feeding difficulty, or seizures rather than the classic muscle cramps seen in older patients. Parents need written instructions describing these signs and a contact number for their prescribing center.

Dosing Protocols Used in Pediatric Practice

No FDA-approved pediatric dosing exists. Published pediatric trials and expert guidelines from the European Society of Pediatric Endocrinology (ESPE) provide the most widely referenced guidance.

The following dosing framework reflects practices reported in the peer-reviewed literature, not an FDA-approved label. Institutional protocols vary, and prescribers should reference their own center's guidelines:

| Indication | Reported Dose | Frequency | Max Single Dose | |---|---|---|---| | Osteogenesis imperfecta | 0.025 to 0.05 mg/kg | Every 6 months | 4 mg | | Fibrous dysplasia | 0.05 mg/kg | Every 6 to 12 months | 4 mg | | Glucocorticoid-induced osteoporosis | 0.025 to 0.05 mg/kg | Every 12 months | 4 mg | | Hypercalcemia of malignancy | 0.04 to 0.06 mg/kg | Single dose, may repeat | 4 mg |

In OI specifically, many centers use a loading approach: two infusions 3 to 6 months apart in the first year, then annual dosing once BMD response is established. [3] [7]

Acute-Phase Reaction: The First-Infusion Phenomenon

The most predictable short-term developmental concern is not skeletal but systemic. An acute-phase reaction (APR) occurs in 25 to 40% of children after their first zoledronic acid infusion. Symptoms include fever (up to 40°C), myalgia, arthralgia, headache, and general malaise typically beginning 12 to 24 hours post-infusion and resolving within 72 hours. [13]

The mechanism involves release of pro-inflammatory cytokines, particularly IL-6 and TNF-alpha, from gamma-delta T cells stimulated by the drug's mevalonate pathway blockade.

Acetaminophen 15 mg/kg every 6 hours (maximum 75 mg/kg/day) or ibuprofen 10 mg/kg every 6 to 8 hours started at the time of infusion reduces APR severity. The reaction is less common after subsequent infusions. Parents should be counseled before the first infusion that a flu-like illness in the following 48 hours is an expected side effect, not an allergic reaction.

Osteogenesis Imperfecta: The Primary Evidence Base

Most of the evidence supporting zoledronic acid use in under-12s comes from OI trials and cohorts. OI is caused by mutations affecting type I collagen, producing bone fragility, frequent fractures, and sometimes severe deformity.

Key Trial Evidence

The Barros 2012 RCT (N=39, ages 3 to 18, OI types I, III, IV) compared zoledronic acid 0.05 mg/kg every 6 months to pamidronate 1 mg/kg/day over 3 days every 3 months. At 12 months, lumbar spine BMD Z-score improved +0.80 SD in the zoledronic acid group vs. +0.95 SD in the pamidronate group. The difference was not statistically significant (P=0.38). Annual fracture rate fell from a mean of 2.8 to 1.1 per patient-year in the zoledronic acid group. [3]

A 2021 systematic review and meta-analysis by Shi et al. (10 studies, N=437 pediatric OI patients) found that IV bisphosphonates (pooled) reduced clinical fracture risk by approximately 35% compared with natural history controls over 24 months, with no significant difference between agents. [14]

What Bisphosphonates Cannot Do in OI

Bisphosphonates increase BMD and reduce fracture rates but do not correct the underlying collagen defect. Bone quality remains abnormal at the microscopic level. The Endocrine Society clinical practice guideline for OI states: "Bisphosphonate therapy reduces fracture frequency in children with moderate-to-severe OI, but evidence of benefit in mild OI (type I) is insufficient to recommend routine treatment." [15]

This distinction matters for under-12s with OI type I, who may have a relatively mild phenotype. Starting a drug with a 10-year skeletal half-life in a 4-year-old with mild OI requires careful consideration of lifetime cumulative skeletal load.

Monitoring Schedule During Treatment

Developmental monitoring in under-12s on zoledronic acid should address bone, kidney, calcium metabolism, growth, and dental health on a defined schedule.

Recommended Monitoring Parameters

Before each infusion:

• Serum creatinine, cystatin C-based eGFR, urinalysis
• Serum calcium, phosphorus, 25-hydroxyvitamin D, PTH
• Weight and height (height velocity calculated)
• Tanner stage documentation

Every 12 months:

• DXA scan (lumbar spine and total body less head) with Z-score reporting using pediatric reference ranges
• Plain radiographs of spine and long bones to assess vertebral morphology and metaphyseal bands
• Dental examination

Every 24 months:

• Bone turnover markers (P1NP, CTX) to assess degree of remodeling suppression
• Review of cumulative lifetime dose and re-evaluation of treatment necessity

When to Pause or Stop Treatment

The decision to continue, pause, or stop zoledronic acid in a child under 12 must be re-evaluated at each treatment cycle. Indications to hold or discontinue include:

• eGFR below 35 mL/min/1.73 m² (per adult prescribing information, applied by expert consensus to children)
• Confirmed pregnancy (relevant for adolescent females approaching puberty)
• Dental surgery requiring bone healing within the next 3 months
• Sustained suppression of bone turnover markers below the pediatric reference range for more than 12 months, suggesting over-suppression
• Achievement of treatment goals (e.g., fracture-free interval of 2 or more years, stable BMD Z-score in an acceptable range)

Drug holidays lasting 1 to 3 years have been used in adults with low fracture risk. Pediatric data on drug holidays are sparse. One retrospective series of 28 children with OI reported that BMD Z-scores declined toward pre-treatment levels within 18 to 24 months of stopping pamidronate, suggesting that continuous or near-continuous treatment may be necessary in severe phenotypes. [16]

Practical Guidance for Clinicians and Families

Starting zoledronic acid in a child under 12 requires shared decision-making involving the child's family, the prescribing specialist (typically a pediatric endocrinologist or pediatric metabolic bone specialist), and the child's primary care physician.

Key communication points include:

• The drug is used off-label. Outcomes data support its use in moderate-to-severe bone fragility disorders, but long-term developmental safety data beyond 5 years are limited.
• The drug will remain in the child's skeleton for years after stopping, including during future pregnancy.
• Annual monitoring visits are not optional. They are the mechanism for detecting growth impairment, renal decline, or over-suppression early.
• Dental hygiene and twice-yearly dental visits reduce the already-small ONJ risk further.

The American Academy of Pediatrics does not currently have a specific policy statement on pediatric bisphosphonate use. Guidance is extrapolated from the Endocrine Society OI guideline and institutional experience at centers such as the Shriners Hospital network and Montreal Children's Hospital. [15]